enGene Q3 Loss Narrows to $0.47/Share; BLA Filing for Detalimogene on Track for 4Q 2026
ENGN sits 29% above its 52-week low of $1.4.
Summary
enGene reported Q3 2026 results with a $32.5M net loss and $266.3M in cash, while confirming its BLA filing for detalimogene is on track for 4Q 2026.
Key Events · Earnings and Guidance · ENGN
-
Q3 Net Loss of $32.5M
Net loss attributable to common shareholders was $32.5 million, or $0.47 per share, for the three months ended July 31, 2026, compared to $29.0 million, or $0.57 per share, a year earlier.
-
Cash Position of $266.3M
Cash, cash equivalents and marketable securities totaled $266.3 million as of July 31, 2026, providing operational flexibility through the planned BLA filing and precommercial readiness.
-
BLA Filing on Track for 4Q 2026
The company plans a data update on key regulatory endpoints, a pre-BLA meeting with the FDA, and initiation of the BLA submission for detalimogene all in 4Q 2026, with a potential FDA approval decision in 2027.
-
Surfactant Cohort Cleared
The detalimogene plus surfactant cohort safety run-in was successfully cleared, and a webinar on preclinical data and cohort enrollment guidance is scheduled for October 15, 2026.
Analysis · ENGN · Life Sciences
enGene reported a Q3 net loss of $32.5 million ($0.47/share) with $266.3 million in cash, and confirmed its pivotal LEGEND data update, pre-BLA meeting, and BLA submission initiation are all planned for 4Q 2026. The company also cleared the surfactant safety run-in and will host a webinar on October 15, 2026. This matters because the BLA filing is the key near-term value driver for detalimogene in BCG-unresponsive NMIBC, and the cash position supports operations through the regulatory milestones.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENGN was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.9M. The 52-week trading range was $1.40 to $12.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.